FDA Grants Accelerated Approval to Pembrolizumab/Trastuzumab Combination for HER2+ Gastric/GEJ Cancers

Based on response data from a randomized phase 3 trial, the FDA granted accelerated approval to pembrolizumab plus trastuzumab and chemotherapy for the treatment of HER2-positive gastric tumors.

The combination regimen of pembrolizumab (Keytruda) plus trastuzumab (Herceptin) and fluoropyrimidine- and platinum-containing chemotherapy was granted accelerated approval by the FDA for the treatment of patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma that is locally advanced or metastatic.

The decision is supported by data from the phase 3 KEYNOTE-811 trial (NCT03615326), which examined trastuzumab plus chemotherapy and either pembrolizumab or placebo as therapy for patients with HER2-positive gastric cancer.

“Today’s approval marks an important milestone, as this is the first time an anti-PD-1 therapy has been approved in combination with anti-HER2 therapy and chemotherapy as a first-line treatment for these patients,” Dr. Roy Baynes, senior vice president and head of global clinical development and chief medical officer at Merck Research Laboratories, said in a press release. “From the start of Keytruda’s development, we have thoughtfully pursued novel combinations to help more patients with cancer. We are pleased to bring a new first-line combination regimen with KEYTRUDA that has shown meaningful improvement in ORR over standard treatment to patients with HER2-positive gastric and GEJ cancer.”

The multicenter, randomized, double-blind study assigned patients 1:1 to receive intravenous pembrolizumab at 200 mg or placebo added to trastuzumab at 8 kg/mg plus fluorouracil at 800 mg/m2 and either cisplatin at 80 mg/m2 or capecitabine at 1000 mg/m2.

The dual primary end points for the trial are progression-free survival and overall survival. The main efficacy data for this analysis were based on the objective response rate, which was significantly improved in the pembrolizumab arm at 74% (95% CI, 66%-82%) versus 52% (95% CI. 43%-61%) in the placebo arm (1-sided P <.0001). Corresponding complete response rates were 11% and 3.1%. These results were statistically significant. Median duration of response was 10.6 months (range, 1.1+ to 16.5+) with pembrolizumab versus 9.5 months (range, 1.4+ to 15.4+) with placebo.

The safety profile of pembrolizumab in this indication is similar to the known safety profile of the agent.

The trial is actively recruiting patients, with a total enrollment goal of 732 patients. Patients must have histologically or cytologically confirmed, previously untreated, locally advanced or metastatic HER2-positive GEJ adenocarcinoma, with HER2-positivity defined as immunohistochemistry 3+ or 2+ in combination with fluorescence in situ hybridization. Patients must have measurable disease per RECIST 1.1, an ECOG performance status of 0 or 1, a life expectancy greater than 6 months, and adequate organ function.


FDA Approves Merck’s KEYTRUDA (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. News release. Merck. May 5, 2021. Accessed May 5, 2021. https://bit.ly/2SjmdOj

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content